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The MDM2 gene is amplified and/or overexpressed in about 10% of glioblastomas and constitutes one of a number of ways the p53
pathway is disrupted in these tumours. MDM2 encodes a nuclear phosphoprotein that regulates several cell proteins by binding and/
or ubiquitinating them, with p53 being a well-established partner. MDM2 has two promoters, P1 and P2 that give rise to transcripts
with distinct 50 untranslated regions. Transcription from P2 is believed to be controlled by p53 and a single-nucleotide polymorphism
(SNP309, T4G) in P2 is reported to be associated with increased risk for, and early development of, malignancies. The use of P1 and
P2 has not been investigated in gliomas. We used RT–PCR to study P1- and P2-MDM2 transcript expression in astrocytic tumours,
xenografts and cell lines with known MDM2, TP53 and p14
ARF gene status. Both promoters were used in all genetic backgrounds
including the use of the P2 promoter in TP53 null cells, indicating a p53-independent induction of transcription. Transcripts from the
P1 promoter formed a greater proportion of the total MDM2 transcripts in tumours with MDM2 amplification, despite these tumours
having two wild-type TP53 alleles. Examination of SNP309 in glioblastoma patients showed a borderline association with survival but
no apparent correlation with age at diagnosis nor with TP53 and p14
ARF status of their tumours. Our findings also indicate that
elevated MDM2 mRNA levels in tumours with MDM2 amplification are preferentially driven by the P1 promoter and that the P2
promoter is not only regulated by p53 but also by other transcription factor(s).
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The evolutionarily conserved MDM2 gene (12q15) encodes a 491
amino-acid nuclear protein, whose activity and cellular localisation is
believed to be controlled by post-translational modifications (Meek
and Knippschild, 2003). For example, phosphorylation of MDM2 at
Ser-166 and Ser-186 by the protein kinase Akt (also known as PKB)
results in nuclear entry (Ashcroft et al, 2002). MDM2 is an E3
ubiquitin ligase, known to negatively regulate p53 by blocking its
trans-activation domain and targeting it for ubiquitination and
proteasome-mediated degradation (Momand et al, 1992; Haupt et al,
1997; Kubbutat et al, 1997). The tumour suppressor protein p14
ARF
associates with and inhibits the E3 ubiquitin ligase activity of MDM2
permitting an accumulation of p53 and a consequent transcriptional
response (Kamijo et al, 1998). MDM2 interacts with many other
proteins including Rb1, E2F1, and the ribosomal proteins L5, L11
and L23, indicating that MDM2 is involved in a complex circuit of
interactions, affecting among others the cell cycle and apoptosis
(Zhang and Zhang, 2005). The details of the control of these
interactions have still to be determined.
MDM2 is amplified and/or overexpressed in a variety of human
tumours of diverse tissue origins (Momand et al, 1998). Up to 10%
of the most malignant astrocytic tumours, glioblastomas (WHO
malignancy grade IV) (Louis et al, 2007) show MDM2 gene
amplification with consequent mRNA overexpression. This is
generally associated with primary (de novo) glioblastomas that
have wild-type TP53 and p14
ARF alleles (Reifenberger et al, 1993;
Ichimura et al, 2000). Consequently, amplification and/or over-
expression of MDM2 is believed to be an alternative mechanism
for escaping p53-regulated control (Ichimura et al, 2000).
MDM2 gene transcription is regulated by two promoters, P1 and
P2. The P1 promoter is located upstream of exon 1 and is active at
basal constitutive levels in most cells (Mendrysa and Perry, 2000).
Although motifs of the P1 promoter important for its activity have
been defined, its control is still not understood (Chang et al, 2004;
Phillips et al, 2006). The second promoter (P2) is located in intron
1, it has two p53-responsive elements (Zauberman et al, 1995)
and p53 is believed to initiate MDM2 transcription from this
promoter, thus forming an auto-regulatory feedback loop. Other
p53-independent mechanisms have also been proposed (Qi et al,
1999; Ries et al, 2000; Phelps et al, 2003, 2005). In addition, a T4G
polymorphism, referred to as SNP309 (rs2279744) in intron 1 of
the human MDM2 gene, has been suggested to affect P2 activity by
increasing the binding affinity of the Sp1 transcription factor
(Bond et al, 2004). This is thought to result in higher MDM2
protein levels, which would potentially attenuate the p53 pathway
and might facilitate cancer formation (Bond et al, 2004).
Transcripts derived from the P1 promoter (P1-MDM2) do
not utilise exon 2 and have exon 1 as their 50 untranslated region
(50 UTR), whereas P2-derived transcripts (P2-MDM2) have exon 2
(Barak et al, 1994). Bases 5–7 of exon 3 form the start codon and
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sare common to transcripts from both promoters. Translation of
transcripts from the P1 promoter is eight-fold less efficient than
translation of the P2 promoter transcripts (Landers et al, 1997),
probably due to the presence of two short upstream open reading
frames located in exon 1 (Jin et al, 2003).
The majority of studies have examined total MDM2 mRNA
expression in normal and tumour tissues (Bueso-Ramos et al,
1995; Broll et al, 1999; Ko et al, 2000; Miyajima et al, 2001). The
individual activity of the P1 and P2 promoters has been
investigated in breast and oral cancer and head and neck
squamous cell carcinoma (Ralhan et al, 2000; Millon et al, 2001;
Okumura et al, 2002), but not in human gliomas. We have assessed
how the gene status of MDM2, TP53 and p14
ARF influences
promoter usage in astrocytic gliomas (primary tumours, glioblas-
toma xenografts, glioblastoma cell lines). In addition, the SNP309
status was studied in glioblastoma patients and correlated to a
number of genetic (i.e., TP53 and p14
ARF) and clinical (i.e., survival
and age at diagnosis) parameters.
MATERIALS AND METHODS
Tumour tissue, xenografts and cell lines
A total of 73 gliomas including 56 glioblastomas (prefixed as GB),
10 anaplastic astrocytomas (prefixed as AA) and 7 astrocytomas
(prefixed as A) were used in the study. In addition, xenografts
from three glioblastomas and three glioma cell lines were studied.
The primary tumours were classified according to WHO classifica-
tion (Louis et al, 2007). Each tumour piece analysed had a
minimum tumour cell content of 75% but generally greater than
90%, as assessed by histology. The tumours have been included
in previous studies using the same identification numbers
(Reifenberger et al, 1993; Ichimura et al, 2000, 2008; Liu et al,
2005). Xenografts hold the same number as the tumour from which
they were derived with the suffix X followed by passage number.
Collection and handling of tumour tissues and xenografts were
as described (Schmidt et al, 1999; Ichimura et al, 2000). The
characteristics of the cell lines Tp365MG and Tp265MG have been
reported elsewhere (Collins, 1983). CCF-STTG1 was purchased
from ATCC (Middlesex, UK). Supplementary Table 1 lists speci-
men numbers and their diagnosis, and indicates in which part of
the study each specimen was used. Table 1 lists the MDM2, TP53
and p14
ARF gene status of the tissues, xenografts and cell lines
used. The study was approved by the Ethical Committee of the
Karolinska Hospital (No. 91:16) and the Cambridge Local
Research Ethics Committee, Cambridge, UK (ref. LREC 03/115).
TP53 analysis by multiplex PCR and MDM2 SNP309
genotyping
DNA extraction from patients’ peripheral blood and cell lines was
as described previously (Ichimura et al, 1996). Multiplex PCR was
performed by amplifying exon 2 (PC1046/PC1047) and exon 5
(PC929/PC931) of the TP53 gene together with exon 35 (PC2419/
PC2420) of an internal control gene (DEPDC5). The latter is known
to be genetically normal in the samples investigated (Seng et al,
2005). Products were carried out on 2% agarose gels and visualised
by ethidium bromide staining. For sequences of the primers used,
see Supplementary Table 2. The MDM2 SNP309 locus (rs2279744)
was genotyped in the peripheral white blood cell DNA of 70 of the
73 astrocytic glioma patients in the series, using previously
published primers and standard PCR conditions (Bond et al,
2004). The T to G variation at the 309th nucleotide of intron 1 of
the MDM2 gene was sequenced using an ABI PRISM 3100-Avant
Genetic Analyser (Applied Biosystems, Warrington, UK) and
Accelrys Gene 2.0 (Accelrys, Cambridge, UK) sequencing analysis
software.
RT–PCR of TP53 and P1- and P2-MDM2 transcripts
Total RNA was extracted from tumour pieces and cell lines as
described (Ichimura et al, 1996). The generation of cDNA and the
PCR conditions for all the experiments have been previously
reported (Ichimura et al, 1996, 2008; Liu et al, 2005). For sequences
of the primers used, see Supplementary Table 2. Primer pairs
PC180/50 and PC446/50 were used to amplify exons 4–9 and exons
7–9 of the TP53 cDNA, respectively. To amplify the P1- and P2-
MDM2 transcripts, forward primers PC3176 and PC3600 in the
non-coding exons 1 or 2, respectively, were used with a common
reverse primer PC3291 (exon 3) or PC3238 (exon 12) of the MDM2
cDNA. Standard cycling parameters (35 cycles) were used for the
qualitative RT–PCR analysis on P1- and P2-MDM2 transcript
expression. Products were carried out on 2% agarose gels and
visualised by ethidium bromide staining. The real-time analysis of
MDM2 mRNA was performed using a LightCycler
R in an identical
manner to that described previously for a similar analysis of other
genes (Ichimura et al, 2008), but using primer pairs PC3176/
PC3291 and PC4570/PC4573 (see Supplementary Table 2) for the
quantitation of P1- and P2-MDM2 transcript levels, respectively.
Statistical analysis
For the statistical analysis, the raw data obtained from the
quantitative RT–PCR analysis were transformed into log2 values.
To assess the effect of MDM2 gene status (amp or no amp) on
P1- and P2-MDM2 mRNA levels, a Mann–Whitney U test was
performed using glioblastomas with MDM2 amplification, wt/wt
TP53 and wt/wt p14
ARF vs glioblastomas with no MDM2 ampli-
fication, wt/wt TP53 and wt/wt p14
ARF. A Mann–Whitney U test
was also used to compare the P1- and P2-MDM2 mRNA expression
within different tumour grades (GBs vs AAs and As) that have no
aberrations on MDM2, TP53 and p14
ARF genes. A two-way ANOVA
was used to test the effect of TP53 and p14
ARF gene status or their
combination on P1 and P2 transcript levels. For the latter test,
tumours were separated into two categories: (i) those with wt/wt
allelic status and (ii) those with at least one defective allele (i.e.,
wt/mut, wt/ , mut/mut, mut/  and  / ). Survival curves were
obtained using the Kaplan–Meier method and statistical differ-
ences were analysed using the log-rank test. A Mann–Whitney
U test was used to compare the age at diagnosis for glioblastomas
in relation to the SNP309 genotype. Differences were accepted as
significant for Po0.05. All statistical analyses were performed
using Minitab 13.0 and SPSS 15.0 software packages.
RESULTS
Transcription from the P2 promoter can be independent of
p53 in astrocytic gliomas
To investigate whether expression using the P2 promoter can
occur in the absence of p53, we studied P1- and P2-MDM2 mRNA
expression in a TP53-null glioma cell line (Tp265MG). Multiplex
PCR and RT–PCR were first used respectively to confirm the TP53
homozygous deletion and lack of endogenous TP53 mRNA in
Tp265MG (Figure 1A and B). To identify the presence of P1- and
P2-derived MDM2 transcripts in Tp265MG, primer sets that
amplify the two distinct 50 UTRs of MDM2 mRNA were used.
Tp265MG was shown to express exon 2-derived transcripts
(Figure 1C), and quantitative PCR confirmed the presence of P2
transcripts albeit at a very low level (Table 1).
In a preliminary study, the promoter usage of the MDM2 gene
was also investigated in a series of primary astrocytic tumours,
comprising of 45 GBs, 5 AAs and 5 As (Supplementary Table 1) as
well as in two additional glioblastoma cell lines (CCF-STTG1 and
Tp365MG) and 3 glioblastoma xenografts (GB217X4, GB181X13
and GB166X1) with known MDM2, TP53 and p14
ARF gene status
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sTable 1 Gene status of MDM2, TP53 and p14
ARF, P1- and P2-MDM2 transcript levels of each specimen and SNP309 genotype and age at diagnosis of the
corresponding patient
Specimen no. MDM2 TP53 p14
ARF P1
a P2
a P1/P2 SNP309 Age at diagnosis
A22 No amp wt/wt wt/wt 0.84 1.01 0.832 G/G NA
A54 No amp wt/wt wt/wt 0.68 2.02 0.337 T/T NA
A25 No amp wt/wt wt/wt 0.42 0.52 0.808 T/T NA
A50 No amp wt/wt wt/wt 0.40 0.63 0.635 G/T NA
A7 No amp wt/wt wt/wt 0.07 0.49 0.143 G/T NA
A23 No amp wt/wt wt/wt 0.58 0.63 0.921 T/T NA
A30 No amp wt/wt wt/wt 0.30 0.24 1.250 T/T NA
AA104 No amp wt/wt wt/wt 1.77 1.05 1.686 G/T NA
AA34 No amp wt/wt wt/wt 2.27 1.02 2.225 T/T NA
AA59 No amp wt/wt wt/wt 0.07 0.27 0.259 T/T NA
AA76 No amp wt/wt wt/wt 0.80 3.42 0.234 G/T NA
AA107 No amp wt/wt wt/wt 0.33 1.89 0.175 G/T NA
AA110 No amp wt/wt wt/wt 6.44 14.07 0.458 G/T NA
AA15 No amp wt/wt wt/wt 0.36 0.73 0.493 T/T NA
AA50 No amp wt/wt wt/wt 0.36 0.44 0.818 T/T NA
AA49 No amp wt/wt  /  NA NA NA NA NA
AA90 No amp  /  wt/wt 0.11 0.230 0.478 G/G NA
GB180 Amp wt/wt wt/wt 25.72 30.9 0.832 G/G 42
GB217 Amp wt/wt wt/wt 12.60 2.77 4.549 G/G 63
GB267 Amp wt/wt wt/wt 4.37 5.73 0.763 T/T 63
GB245 Amp wt/wt wt/wt 9.30 6.34 1.467 T/T 61
GB246 Amp wt/wt wt/wt 18.28 9.4 1.945 G/T 62
GB35 Amp wt/wt wt/wt 41.60 9.52 4.370 G/T 71
GB37 Amp wt/wt wt/wt 50.68 13.86 3.657 T/T 40
GB90 Amp wt/wt wt/wt 65.46 11.44 5.722 T/T 61
GB140 Amp wt/wt wt/  9.91 5.66 1.751 G/T 42
GB223 Amp wt/wt wt/  4.02 8.26 0.487 T/T 65
GB7 Amp wt/wt wt/  129.97 12.06 10.777 T/T 41
GB81 Amp wt/wt wt/  23.76 12.95 1.835 T/T 65
GB237 Amp wt/  wt/wt NA NA NA G/T 73
GB96 No amp wt/wt wt/wt 0.42 2.04 0.206 G/G 51
GB75 No amp wt/wt wt/wt 0.77 0.69 1.116 T/T 31
GB149 No amp wt/wt wt/wt 0.74 1.84 0.402 G/T 61
GB247 No amp wt/wt wt/wt 0.64 1.85 0.346 G/T 34
GB250 No amp wt/wt wt/wt 0.83 2.64 0.314 T/T 12
GB30 No amp wt/wt wt/  NA NA NA G/G 37
GB144 No amp wt/wt  /  1.20 5.36 0.224 T/T 58
GB24 No amp wt/wt  /  0.14 1.64 0.085 G/T 61
GB18 No amp wt/wt  /  0.55 0.74 0.743 G/T 51
GB3 No amp wt/wt  /  2.66 3.72 0.715 T/T 67
GB32 No amp wt/wt  /  2.09 1.95 1.072 T/T 47
GB34 No amp wt/wt  /  0.45 1.77 0.254 T/T 72
GB52 No amp wt/wt  /  0.14 1.65 0.085 T/T 71
GB56 No amp wt/wt  /  1.76 3.08 0.571 G/T 58
GB57 No amp wt/wt  /  1.16 2.13 0.545 G/T 55
GB63 No amp wt/wt  /  0.75 1.83 0.410 G/G 74
GB8 No amp wt/wt  /  0.67 1.76 0.381 G/T 63
GB84 No amp wt/wt  /  0.57 2.77 0.206 G/T 72
GB94 No amp wt/wt  /  0.91 4.78 0.190 G/T 50
GB41 No amp wt/wt  /  0.28 0.75 0.373 G/T 70
GB9 No amp wt/wt  /  1.19 2.47 0.482 T/T 68
GB1 No amp wt/wt  /  NA NA NA NA NA
GB51 No amp wt/   /  NA NA NA T/T 70
GB46 No amp wt/mut wt/wt 0.07 0.36 0.194 T/T 46
GB59 No amp wt/mut wt/wt 1.14 5.03 0.227 T/T 51
GB221 No amp wt/mut wt/wt 0.10 0.48 0.208 G/T 48
GB193 No amp wt/mut wt/  0.37 1.43 0.259 G/T 56
GB27 No amp mut/mut wt/wt 1.61 0.47 3.426 T/T 31
GB164 No amp mut/  wt/wt 0.29 1.96 0.148 G/T 63
GB61 No amp mut/  wt/wt 3.00 1.45 2.069 T/T 68
GB103 No amp mut/  wt/wt 4.84 1.32 3.667 G/T 72
GB131 No amp mut/  wt/wt 1.37 3.63 0.377 T/T 68
GB29 No amp mut/  wt/  0.09 0.93 0.097 T/T 45
GB132 No amp mut/  wt/  1.51 2.5 0.604 G/T 52
GB17 No amp wt/mut  /  0.86 0.61 1.410 G/T 62
GB138 No amp wt/mut  /  0.22 0.36 0.611 G/G 55
GB22 No amp wt/mut  /  0.31 0.71 0.437 T/T 43
GB5 No amp wt/mut  /  1.07 1.29 0.829 T/T 56
GB4 No amp wt/mut  /  NA NA NA NA NA
GB166 No amp mut/   /  0.31 0.5 0.620 T/T 68
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susing promoter-specific primers. Both P1- and P2-derived
transcripts were detectable in all the samples including the
tumours and xenografts that lack wild-type TP53 (Supplementary
Figure 1 and data not shown).
The majority of the primary tumours (67 of 73), the xenografts
GB217X4 and GB166X1 and the cell line Tp265MG were examined
by real-time PCR analysis confirming the P1- and P2-MDM2 usage
(Table 1 and Supplementary Table 1). The P1/P2 ratio varied
markedly from specimen to specimen, as might be expected due to
the different known status of components of the p53 pathway and
the content of normal cells in tumour specimens. The P1/P2 ratio
was maximum in the Tp265MG cell line (Table 1). While it might
be argued that in the tumour tissue samples analysed, all P2-
derived transcripts originated from the normal cells (i.e.,
endothelial cells, pericytes, macrophages and so on) present, the
P2 transcripts from the Tp256MG line and the GB166X1 xenograft
(no wild-type TP53 and use of human specific primers) could only
have originated from the tumour cells. In addition, it is interesting
that the transcripts in AA90 (homozygous deletion of TP53) show
a P1/P2 ratio of 0.47. Overall, these findings provide evidence that
p53 is not necessary for low-level P2-MDM2 transcription in
astrocytic glioma cells.
Variation in the usage of the P1 and P2 promoters in
astrocytic gliomas
Tumours with MDM2 amplification were grouped and compared
to those with no MDM2 amplification. This comparison showed a
statistically significant increase in mRNA levels from both the P1
promoter (P¼0.004, Mann–Whitney U test, Figure 2A) and the P2
promoter (P¼0.004, Mann–Whitney U test, Figure 2B) in the
MDM2-amplified group. This indicates that both promoters are
utilised in cases with amplification of the MDM2 gene. We next
compared changes in the P1/P2 ratio in the same groups (Table 1).
There was a significant difference in the P1/P2 ratio between
tumours with MDM2 amplification as compared to those without
amplification (P¼0.01, Mann–Whitney U test, Figure 2C), indi-
cating that the elevated MDM2 mRNA expression seen in the
MDM2-amplified astrocytic tumours is not equally driven by both
promoters. MDM2 amplification had a higher impact on P1 than
P2 expression, as indicated from the comparison of the medians of
(a) P1 expression in the amplified cases (median¼22) vs P1 in the
non-amplified cases (median¼0.74) and (b) P2 expression in the
amplified cases (median¼9.46) vs P2 in the non-amplified cases
(median¼1.85).
The effect of TP53 and p14
ARF gene status was then investigated
to evaluate whether any TP53 mutation (wt/mut, mut/mut or
mut/ ), p14
ARF hemi- and nullizygosity (wt/  or  / )o ra
combination of the two have an effect on P1 and/or P2 transcript
levels. A two-way ANOVA indicated that any TP53 mutation was
significantly associated with lower P2-MDM2 mRNA levels
(P¼0.014, two-way ANOVA, Figure 2D) and did not affect the
activity of the P1 promoter (P¼0.575, two-way ANOVA). This was
also observed when changes in the P1/P2 ratio were examined with
a correlation seen between TP53 gene status and the P1/P2 ratio
(P¼0.039, two-way ANOVA, Figure 2E). Neither the p14
ARF
gene status alone nor the combination of TP53 and p14
ARF
aberrations had any significant correlation with P1 or P2 transcript
expression, nor with P1/P2 ratio (P40.05, two-way ANOVA).
Finally, we tested whether there is a difference in the P1-, P2- or
P1/P2 ratio of MDM2 mRNA among high-grade (GBs) vs lower-
grade gliomas (AAs and As) with no MDM2 gene amplification
and wild-type TP53 and p14
ARF genes. No statistical difference
was observed (P40.05, Mann–Whitney U test), suggesting
that tumour grade does not affect MDM2 mRNA expression in a
TP53 and p14
ARF wild-type background.
The P2 promoter polymorphism (SNP309) does not appear
to be significant in astrocytic gliomas
To document the incidence of the SNP309 (rs2279744) poly-
morphism in astrocytic gliomas, DNA from peripheral white blood
cells of 70 primary cases was studied (Supplementary Table 1). In
addition to these, a glioblastoma cell line (Tp265MG) and a
glioblastoma xenograft (GB181X13) were also investigated.
Table 1 summarises the genotypes obtained. Of the 70 patients
genotyped for the SNP309, 34 (48.5%) were T/T, 27 (38.5%) were
G/T and 9 (12.8%) were G/G. These frequencies are very similar to
those seen in healthy Caucasian volunteers (48% T/T, 40% T/G and
12% G/G) (Bond et al, 2004). Notably, TP53-null specimens,
Tp265MG (see above) and AA90 (confirmed by array-CGH,
manuscript in preparation) were homozygous for the variant G
allele.
To examine the effect of SNP309 on MDM2 expression, we
compared the levels of P2-MDM2 mRNA in glioblastomas without
MDM2 gene amplification in relation to SNP309 genotype
(Figure 2F). The results showed that glioblastomas homozygous
for G/G did not have significantly higher levels of P2-MDM2
mRNA expression when compared to glioblastomas homozygous
for T/T at this locus. Overall, the expression levels between the
different SNP309 genotypes (T/T, G/T and G/G) did not appear to
be substantially affected by the polymorphism at this locus.
As shown by others (Bond et al, 2004; Swinney et al, 2005) the
age of cancer formation in patients with SNP309 (G/G) can vary
greatly from those individuals with a T/T genotype. We compared
the age distribution at the time of diagnosis for 54 glioblastoma
patients who had homozygous T/T genotype with that of patients
who had either heterozygous (G/T) or homozygous (G/G) variant
Table 1 (Continued)
Specimen no. MDM2 TP53 p14
ARF P1
a P2
a P1/P2 SNP309 Age at diagnosis
GB16 No amp mut/   /  0.14 0.12 1.167 G/T 73
GB33 No amp mut/   /  0.52 0.41 1.268 G/G 66
GB55 No amp mut/   /  1.42 2.01 0.706 T/T 74
GB217X4
b Amp wt/wt/wt wt/wt 28.8 2.58 11.162 NA NA
GB181X13
b No amp wt/wt  /  NA NA NA T/T NA
GB166X1
b No amp mut/   /  0.03 0.44 0.068 NA NA
CCF-STTG1
c Amp wt/wt wt/  NA NA NA NA NA
Tp365MG
c Amp wt/wt wt/  NA NA NA NA NA
Tp265MG
c No amp  /   /  0.41 0.01 41 G/G NA
A¼astrocytoma; AA¼anaplastic astrocytoma; GB¼glioblastoma; no amp¼no amplification; amp¼amplification (X 5 copies); wt/wt¼two wild-type copies;  / ¼
homozygous deletion (see text); wt/ ¼loss of one allele; wt/mut¼retention of one wild-type allele and one mutated allele; mut/mut¼both alleles with unique mutations;
mut/ ¼loss of one allele and retained allele mutated; NA¼not applicable.
aNormalised target/reference (MDM2/18S) ratio.
bGlioblastoma xenografts hold the same number
as the tumour from which they were derived with the suffix X followed by passage number.
cGlioblastoma cell lines.
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sgenotypes at SNP309 (Table 1). The median age at diagnosis was
identical for T/T genotype and G/T or G/G genotype (61 years).
There was no association between T and G carriers in relation to age
at diagnosis in glioblastomas (P¼0.658, Mann–Whitney U test).
A Kaplan–Meier analysis was performed to test if the
occurrence of this gene alteration had an effect on the prognosis
of the glioblastoma patients. Patients without the polymorphism
(T/T) showed a median survival of 337 days, whereas patients
carrying a G allele (G/T or G/G) had a median survival of 193 days.
Even though the median survival values appear quite different,
only a borderline statistical association (P¼0.052) in the Kaplan–
Meier curves from glioblastomas with T/T compared with a G/G or
G/T genotype could be shown in the relatively small group (n¼54)
(Figure 3A). In addition, the effect on survival of G/G (as compared
to G/GþG/T) against T/T in glioblastoma patients was also tested
and no significant association was observed (P¼0.341, log-rank
test). Although it has been suggested that the oestrogen signalling
pathway allows the G allele to accelerate tumour formation in
women (Bond and Levine, 2007), while our data did not include
any G/G females, a preliminary comparison of the G/T against T/T
female patients with glioblastoma did not show any association
with survival (P¼0.748, log-rank test).
A prognostic value of TP53 gene status in relation to SNP309
genotype has not been demonstrated in glioblastomas. Therefore,
we investigated whether SNP309 status might interact with
differing TP53 status to modify the survival of glioblastoma
patients. Of the 54 glioblastomas analysed, 35 (65%) had wild-type
TP53 (wt/wt or wt/ ) and 19 (35%) had at least one mutated TP53
allele (wt/mut, mut/  or mut/mut). As shown by Kaplan–Meier
analyses, SNP309 status did not affect the association between
TP53 gene status and survival in glioblastomas (Figure 3B).
We also examined the impact of p14
ARF gene status, as it is one
of the central nodes in the p53 pathway. In the glioblastoma series
studied, 22 of 54 (41%) had wild-type p14
ARF alleles, whereas 32 of
54 (59%) had lost at least one wild-type p14
ARF allele. As shown in
Figure 3C, SNP309 status did not act synergistically with p14
ARF
gene status to significantly alter survival in glioblastomas.
DISCUSSION
The usage of the two promoters of the MDM2 gene was analysed
here for the first time in astrocytic tumours, glioblastoma
xenografts and glioblastoma cell lines with known MDM2, TP53
and p14
ARF gene status. By documenting P1- and P2-MDM2-
induced transcripts in a glioblastoma cell line (Tp265MG) with no
MDM2 gene amplification and homozygously deleted TP53 and
p14
ARF, it was demonstrated that exon 2-derived transcripts, that
is, transcripts initiated from the supposedly p53-responsive
promoter (P2), were detectable even in the complete absence of
all protein products of the TP53 gene. Similar findings were made
in an anaplastic astrocytoma case (AA90) with no MDM2 gene
amplification, homozygously deleted TP53 and two wild-type
copies of p14
ARF (Table 1). In addition, GB103 retains only one
allele of TP53 with the R175H mutation (Backlund et al, 2003) and
the tumour also expresses MDM2 transcripts from the P2
promoter. The R175H mutation would affect all known splice
variants of TP53 (Bourdon et al, 2005) and has been shown to be
transactivation defective (Soussi and Wiman, 2007).
P1- and P2-induced transcripts were expressed from other
astrocytic gliomas of the series, which also lacked wild-type TP53.
There were seven glioblastoma cases (GB164, GB61, GB131, GB29,
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Figure 1 Agarose gels electrophoresis of PCR products confirming the
homozygous deletion of TP53 in Tp265MG and showing that expression
from the P2 promoter is independent of TP53 status. (A) Multiplex PCR
using genomic DNA as template and independent pairs of primers
(Supplementary Table 2) for exons 2 and 5 of TP53, and an unrelated
retained locus (DEPDC5), confirming the homozygous deletion of TP53 in
Tp265MG. (B) RT–PCR analysis of TP53 transcripts encompassing exons
4–9 and exons 7–9 of the TP53 cDNA showing that no TP53 mRNA was
detectable in Tp265MG. cDNA from the GB181X13 xenograft (TP53
wt/wt)
was used as a control template. (C) RT–PCR analysis of MDM2 transcripts
using a forward primer located in either exon 1 (PC3176; 50 P1 promoter)
or exon 2 (PC3600; 50 P2 promoter) with a common reverse primer
(PC3238; sequence equivalent to 30 UTR) and cDNA as template to
amplify P1- and P2-MDM2 transcripts in Tp265MG. cDNA from
GB181X13 (TP53
wt/wt, expected to express MDM2 mRNA from both
promoters) was used as a control. Note that MDM2 transcripts are
expressed from both P1 and P2 promoters in Tp265MG glioma cell line
and in GB181X13.
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sGB166, GB16 and GB33) that showed loss of one TP53 allele and
mutation of the DNA-binding domain in the retained allele
(Ichimura et al, 2000; Backlund et al, 2003). Such mutations affect
all the proteins encoded by TP53 transcript variants (Bourdon
et al, 2005). While there is no information about the impact on
function of the specific mutations affecting each case, these seven
tumours can only generate mutant p53 tetramers, which according
to the model proposed by Chan et al (2004) will be inactive.
Finally, GB132 retained only one mutated TP53 copy (R342X),
affecting the sequence coding for the p53 oligomerisation domain,
and this would prevent the formation of full-length p53 tetramers
and the oligomerisation of the six other isoforms known to utilise
this region of code (i.e., p53b, p53g, D40p53b, D40p53g, D133p53b
and D133p53g), but would not impact on two p53 isoforms
(i.e., D40p53 and D133p53) (Ichimura et al, 2000; Backlund et al,
2003; Bourdon et al, 2005).
While it can be argued that the P2-derived MDM2 transcripts
came from normal cells present in the tumour tissue analysed,
both the Tp265MG cell line and the GB166X1 xenograft contain no
normal human cells, yet both expressed the P2 transcripts (primers
used for analysis of the xenografts were human-sequence specific)
and this would argue for at least some of the P2 transcripts coming
from the tumour cells themselves. Overall, our findings provide
evidence that (i) wild-type p53 is not necessary to induce MDM2
transcription through the p53-responsive promoter (P2) and that
(ii) other transcriptional factor(s) can regulate MDM2 mRNA
expression through P2 in astrocytic gliomas that lack endogenous
p53 protein expression.
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Figure 2 Box plot diagrams showing the distribution of the MDM2 mRNA levels (i.e., P1, P2 or P1/P2) obtained for glioblastomas in relation to their
MDM2 gene status (amplification or no amplification), TP53 gene status (wild-type or mutation) and SNP309 genotype (T/T, G/T or G/G). The upper and
lower limits of the boxes and the line across the boxes indicate the 75th, 25th percentiles and the median, respectively. The upper and lower horizontal bars
indicate the 95th and 5th percentiles, respectively. Outliers are illustrated as circles. P-values are indicated at the top of the plots and were determined using
the Mann–Whitney U test or the two-way ANOVA (see ‘Results’ section for details). (A and B) Log2 P1- and Log 2 P2-MDM2 mRNA expression in
glioblastomas with and without MDM2 gene amplification. (C) P1/P2 MDM2 mRNA ratio in glioblastomas with and without MDM2 gene amplification. (D)
Log2 P2-MDM2 mRNA expression in glioblastomas with wild-type or mutated TP53.( E) P1/P2 MDM2 mRNA ratio in glioblastomas with wild-type or
mutated TP53.( F) P2-MDM2 mRNA expression levels in glioblastomas with no MDM2 amplification in relation to their T/T, G/T or G/G genotypes for the
SNP309 locus. Expression levels were measured as described in the ‘Materials and Methods’ section. There was no statistically significant difference in the
expression levels between the T/T, G/T or G/G genotypes.
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sStudies have shown that different p73 isoforms can trans-
activate the P2-MDM2 promoter in p53-null cells (Zhu et al, 1998;
Alarcon-Vargas et al, 2000; Wang et al, 2001), although this
is debated (Yu et al, 1999). The TP73 gene is located at 1p36, a
region reported to show deletions in astrocytic gliomas
(Barbashina et al, 2005). However, this series of cases has been
studied in detail as to their copy-number status at 1p36 and
this has shown that the majority of the tumours have two copies
of TP73 (Ichimura et al, 2008). The 13 cases that had only one
copy of TP73 (A50, A23, A30, AA34, AA49, GB96, GB250, GB3,
GB52, GB56, GB63, GB84 and GB41) retained two wild-type copies
of TP53 (Ichimura et al, 2008). Thus, the p53-independent
expression of P2-MDM2 could be explained by p73 in astrocytic
gliomas. Less is known about the TP63 gene, but the p63a iso-
form has also been shown to weakly activate the MDM2 promoter
in H1299, a p53-null non-small cell lung carcinoma cell line
(Dohn et al, 2001).
Other functional, p53-independent elements have been reported
in the P2 promoter. These include two thyroid hormone response
elements (Qi et al, 1999) and an AP1-ETS motif together with a
non-conserved upstream repeat sequence (nnGGGGC)5 (Phelps
et al, 2003). At present, there are no data to indicate the relevance
of p53-independent cis-acting elements for P2-MDM2 promoter
activity in gliomas with no wild-type TP53.
In an attempt to provide further insights into the contribution of
P1 and P2 promoters on the regulation of MDM2 mRNA
expression in astrocytic gliomas, quantitative RT–PCR analysis
was used. Amplification of the MDM2 gene in glioblastomas
with wild-type TP53 and p14
ARF alleles was clearly reflected at the
transcriptional level. Although expression from both promoters
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Figure 3 SNP309 in relation to glioma tumourigenesis. (A) Survival curves of patients with glioblastoma, comparing those with T/T to those with G/G or
G/T for MDM2 SNP309. A borderline association in survival based on the presence or absence of the G allele was observed. (B) MDM2 SNP309 genotype
in glioblastomas and TP53 status (i.e., wild-type or mutation) in relation to survival. (i) Survival curves of glioblastoma patients with the common SNP309
genotype (T/T) by TP53 gene status. (ii) Survival curves of glioblastoma patients with the variant SNP309 genotype (G/T or G/G) by TP53 gene status. (C)
MDM2 SNP309 genotype of glioblastomas and p14
ARF gene status (i.e., wild-type or hemi/nullizygosity) in relation to survival. (i) Survival curves of
glioblastoma patients with the common SNP309 genotype (T/T) by p14
ARF gene status. (ii) Survival curves of glioblastoma patients with the variant SNP309
genotype (G/T or G/G) by p14
ARF gene status. The crosses indicate censored patients. Note that no significant difference was observed in survival in
conjunction with TP53 or p14
ARF gene status.
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swas increased in cases with MDM2 amplification, the amplification
event had a higher impact on the P1 promoter. Assuming that the
MDM2/p53 autoregulatory negative feedback loop is functional at
the protein level in astrocytic tumours with amplified copies of the
MDM2 gene, one would expect the P1 promoter to give rise to high
MDM2 mRNA and protein levels in these neoplasms, as all MDM2
gene coded proteins with a p53-binding domain would inhibit the
transcriptional activation of the P2 promoter by p53, reducing
MDM2 mRNA expression from this promoter. This would result
in higher MDM2 mRNA levels from the P1 promoter, as was
observed.
Importantly, there also appeared to be a clear correlation between
P2-MDM2 transcript levels and TP53 gene status (Figure 2D). The
statistical analyses of these data are in agreement with two
independent studies in oral squamous cell carcinomas and in cell
lines established from head and neck cancers or sarcomas, where
P2-MDM2 transcript levels correlated with TP53 gene status (Ralhan
et al, 2000; Millon et al, 2001). In contrast, very little correlation was
observed between P1/P2 values and p53 mutational status in human
breast cancer specimens (Okumura et al, 2002).
Overall, it would seem that complete loss of wild-type p53 is
not sufficient to inhibit the P2 promoter in astrocytic gliomas.
Thus, P2 transcripts cannot be used to predict the presence of
transcriptionally active p53 in astrocytic gliomas as has been
suggested in other tumours by some authors (Bull et al, 1998;
Millon et al, 2001).
In an attempt to further understand control of the P2 promoter
in these tumours, we examined the SNP309 (rs2279744). This
polymorphism in the P2 promoter has been found to affect the
binding of the Sp1 transcription factor to the promoter sequence
and the G allele has been associated with increased binding of Sp1
and expression of MDM2 transcripts and protein. The G allele has
also been associated with accelerated tumour formation in both
hereditary and sporadic cancers in humans (Bond et al, 2004).
Sequencing of the SNP309 region of the P2 promoter in the
peripheral blood white cell DNA of 70 astrocytic glioma patients
showed that 48% of the patients were homozygous for T/T, 38%
heterozygous for T/G and 12% homozygous for G/G. These
frequencies were similar to the small cohort of healthy Caucasian
volunteers studied by Bond et al (2004). Interestingly, both
Tp265MG and AA90 with homozygous deletion of TP53 were
homozygous for the G allele. The T to G substitution, which
increases the binding affinity of the Sp1 transcriptional activator,
might facilitate MDM2 mRNA expression from the P2 promoter in
these samples. However, the P2-MDM2 expression observed in
astrocytic gliomas with no wild-type TP53 cannot be solely
explained by the involvement of the Sp1 trans-acting factor, as 5
of 9 (55.5%) of these cases were found to be homozygous for the T
allele (Table 1).
The G/G and G/T SNP309 in patients with glioblastoma showed
a borderline association with poorer survival but no correlation
with age at diagnosis or with the TP53 and p14
ARF status of their
tumours. Our data are in agreement with three independent
studies, where SNP309 was shown not to have a significant
involvement in glioma tumourigenesis (El Hallani et al, 2007;
Tsuiki et al, 2007; Idbaih et al, 2008). Null results have also been
reported in other types of cancer in relation to this polymorphism
(Campbell et al, 2006; Petenkaya et al, 2006; Pine et al, 2006;
Talseth et al, 2007).
Finally, to examine the effect of the SNP309 polymorphism on
MDM2 expression, the MDM2 mRNA transcriptional levels
obtained by quantitative RT–PCR analysis were compared with
SNP309 genetic status. In contrast to previous reports (Bond et al,
2004; Hong et al, 2005; Sanchez-Carbayo et al, 2007), the data did
not show that G/G patients have a significantly higher P2-MDM2
mRNA expression levels as compared with the levels seen in
astrocytic glioma patients with the T/T genotype. Overall, larger,
prospective studies are needed to verify whether there is a clear
involvement of this or other MDM2 polymorphism(s) in glioma
tumourigenesis.
In summary, we report that both the P1 and P2 promoters are
used in all genetic backgrounds, including the use of the P2
promoter in TP53-null cells, indicating a p53-independent induction
of transcription from P2. In glioblastomas with amplification of the
MDM2 gene, transcripts from the P1 promoter dominate despite all
such cases having two wild-type TP53 alleles. We also found no clear
correlation between the SNP309 (rs2279744) locus in MDM2 and age
of presentation or survival in glioblastoma patients.
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